<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161479">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952795</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-DHE-2011-42</org_study_id>
    <nct_id>NCT01952795</nct_id>
  </id_info>
  <brief_title>Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle</brief_title>
  <official_title>Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of diet and physical exercise program
      on pregnancy rate and live birth in obese women who undergo an IVF cycle.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pregnancy rate by cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperstimulation rate</measure>
    <time_frame>At luteal phase and first weeks of pregnancy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with moderate or severe hyperstimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertility rate</measure>
    <time_frame>24 hours post pick up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of mature oocytes fertilized by conventional IVF or ICSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mature oocytes</measure>
    <time_frame>Pick up day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of total mature oocytes obtained after stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate</measure>
    <time_frame>Durinf the stimulation in follicular phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stimulated Patients who fail to perform the follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good quality embryos</measure>
    <time_frame>Day 3 to 5  post pick up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of good quality embryos obtained (A and B) by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>First trimester of pregnancy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of non evolutive pregnancies during the first trimester</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>Between 7 a 9 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amount of patients who finish the treatment with a live newborn</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Leptin, adiponectin, resistin, interleukin VI, TNF-α, visfatin, IGF1 and PAI I</measure>
    <time_frame>During the stimulation phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study the relationship between obesity and measurable surrogate parameters the same as the products of secretion of fat (leptin, adiponectin, resistin, interleukin VI, TNF-α, visfatin, IGF1 and PAI I) or with inflammatory parameters results of an IVF cycle.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Diet and exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total caloric intake aimed at maintaining a diet with&gt; 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet and exercise</intervention_name>
    <arm_group_label>Diet and exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who want pregnancy.

          -  Basal FSH levels ≤ 10 IU / l.

          -  Infertility to justify treatment with IVF/ICSI.

          -  Being included in a long protocol with GnRH agonist.

          -  Presence of both ovaries and uterus able to support embryo implantation and
             pregnancy.

          -  Body mass index (BMI) ≥ 30 kg/m2 and ≤ 35 kg/m2.

          -  Absence of pregnancy before starting ovarian stimulation.

          -  Having given their written consent.

        Exclusion Criteria:

          -  Female age ≤ 18 years and ≥ 35 years.

          -  Severe male factor not permit an IVF-ICSI with ejaculated sample.

          -  Patients with low ovarian reserve (basal FSH levels ≥ 10 IU / l or lower antral
             follicle count to 6 follicles in both ovaries).

          -  HIV seropositivity, HBV or HCV.

          -  Clinically important disease.

          -  Having frozen embryos from previous cycles of assisted reproduction.

          -  Unexplained vaginal bleeding.

          -  Poor response in previous IVF cycles with standard stimulation protocols

          -  Any contraindication to become pregnant.

          -  Known allergy to preparations of gonadotropins or its excipients.

          -  High consumption of alcohol, drugs or psychotropic drugs.

          -  Concurrent participation in another study.

          -  Patients who have done previous cycles of IVF / ICSI without success
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan José Espinós-Gómez, MD</last_name>
    <phone>+34607163031</phone>
    <email>jespinos@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Polo, MD</last_name>
    <phone>+34696605770</phone>
    <email>apolo@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Polo, MD</last_name>
      <phone>+34696605770</phone>
      <email>apolo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Juan José Espinós-Gómez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Polo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
